Varicella-zoster vaccine [16]

New England Journal of Medicine

Volumn 357, Issue 1, 2007, Pages 89-

  Lang, Pierre Olivier ^a   Herrmann, François ^a   Michel, Jean Pierre ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANALGESIC AGENT; VALACICLOVIR; ANTIVIRUS AGENT; VARICELLA ZOSTER VACCINE;

CHICKENPOX; CLINICAL TRIAL; HERPES ZOSTER; HOSPITAL PATIENT; HUMAN; INCIDENCE; LETTER; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; TREATMENT OUTCOME; AGED; FEMALE; HOSPITALIZATION; MALE; NEURALGIA; NOTE;

AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; FEMALE; HERPES ZOSTER; HERPES ZOSTER VACCINE; HOSPITALIZATION; HUMANS; MALE; NEURALGIA;

EID: 34347382739     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (2)

1. Chidiac C, Bruxelle J, Daures JP, et al. Characteristics of patients with herpes zoster on presentation to practitioners in France. Clin Infect Dis 2001;33:62-9.
2. de Melker H, Berbers G, Hahné S, et al. The epidemiology of varicella and herpes zoster in the Netherlands: implications for varicella zoster virus vaccination. Vaccine 2006;24:3946-5.